BUSINESS

• Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
  May 14, 2021

• Daiichi Sankyo Seeks Central Neuropathic Pain Use for Tarlige
  May 14, 2021

• Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
  May 14, 2021

• Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President
  May 14, 2021

• Mitsubishi Tanabe Incurs Operating Loss 2 Years Running as Parkinson’s Write-Down Weighs
  May 13, 2021

• Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
  May 13, 2021

• Eisai Logs 58.8% Drop in Operating Profit as Merck Milestone Dips on Lenvima Miss
  May 13, 2021

• Sawai Group Aims to Double Sales to 400 Billion Yen by FY2030: New Long-Term Vision
  May 13, 2021

• 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
  May 13, 2021

• Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga
  May 12, 2021

• Takeda’s FY2020 Profits Jump on Non-Core Divestitures, Post-Shire Cost Synergies
  May 12, 2021

• Ono Chief Questions Yet Another Re-Pricing for Opdivo, 11.5% Cut in August
  May 12, 2021

• Fuji Yakuhin Out-Licenses Hyperuricemia Med Dotinurad to US Biotech
  May 12, 2021

• Shionogi Chief Eyes Conditional Approval for COVID-19 Vaccine, Supply by Year’s End If OK’ed
  May 11, 2021

• Chugai, Japan Govt Cut Supply Deal for COVID-19 Antibody Cocktail
  May 11, 2021

• Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
  May 11, 2021

• Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
  May 11, 2021

• Daiichi Sankyo’s DS-1062 Notches Positive PI Data in Triple Negative Breast Cancer
  May 11, 2021

• Lawyer Hiroaki Tanaka Tapped to Lead Kobayashi Kako in Management Reshuffle
  May 11, 2021

• Maruishi to Curb Supply of 5 Sedative Products due to Increase in Severe COVID-19 Cases
  May 11, 2021

ページ

• « 先頭
• ‹ Prev
• …
• 232
• 233
• 234
• 235
• 236
• 237
• 238
• 239
• 240
• …
• Next ›
• 最終 »